Our partner, Oragenics, Inc., has announced completion of enrollment of its Phase 2 clinical trial for AG013 in oral mucositis
ActoBio Therapeutics™ has a rich pipeline of therapeutic agents, called ActoBiotics®, that are developed to treat a number of diseases, focusing primarily on disease areas with high unmet needs in immunotherapy, allergy and immune tolerance induction.
ActoBiotics® are based on the well-characterized, safe food-grade bacterium Lactococcus lactis. They are specifically designed and engineered to perform very specific biological interventions across broad therapeutic applications.